Lenvakast — Lenvatinib 4 mg
Lenvakast 4 mg contains Lenvatinib, a multiple receptor tyrosine kinase inhibitor. Manufacturer: Aprazer Healthcare (India). Generic version of Lenvima.
Dosage Flexibility:
The 4 mg capsule is the fundamental unit for dosing. Since Lenvatinib dosages vary widely (from 4 mg to 24 mg daily) depending on the cancer type and patient weight, this strength allows for precise dose adjustments.
✅ Action: It simultaneously inhibits VEGFR, FGFR, and other kinase receptors to stop tumor angiogenesis (blood vessel growth).
Indicated for the treatment of:
- Differentiated Thyroid Cancer (DTC): Radioiodine-refractory cases.
- Hepatocellular Carcinoma (HCC): First-line treatment for unresectable liver cancer.
- Renal Cell Carcinoma (RCC): In combination with Everolimus for advanced kidney cancer.
Strength: 4 mg per capsule.
Common Daily Regimens:
- Thyroid Cancer (24 mg): Take 6 capsules once daily.
- Liver Cancer (Body weight ≥ 60 kg): 12 mg (3 capsules) once daily.
- Liver Cancer (Body weight < 60 kg): 8 mg (2 capsules) once daily.
⚠️ Instructions: Take once daily at the same time, with or without food. Swallow whole; do not open, crush, or chew.
- Uncontrolled Hypertension (High Blood Pressure).
- Severe hepatic impairment (Child-Pugh C) or renal failure.
- History of Fistula or Gastrointestinal Perforation.
- Pregnancy and breastfeeding.
Hypertension is the most common adverse reaction. Blood pressure should be well-controlled prior to treatment and monitored regularly.
Other side effects:
- Proteinuria: Protein in urine (requires regular testing).
- Diarrhea and fatigue.
- Palmar-plantar erythrodysesthesia: Hand-foot syndrome (redness/peeling of skin).
What Customers Say
No reviews yet
Your review can be the first!